Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · IEX Real-Time Price · USD
4.280
-0.040 (-0.93%)
At close: May 6, 2024, 4:00 PM
4.349
+0.069 (1.61%)
After-hours: May 6, 2024, 7:31 PM EDT
Sagimet Biosciences Revenue
In the year 2023, Sagimet Biosciences had annual revenue of $2.00M.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
68.30
Revenue / Employee
$250,000
Employees
8
Market Cap
136.59M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.00M | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSGMT News
- 1 day ago - Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer - GlobeNewsWire
- 15 days ago - Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 - GlobeNewsWire
- 5 weeks ago - Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat - GlobeNewsWire
- 6 weeks ago - Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors - GlobeNewsWire
- 6 weeks ago - Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock - GlobeNewsWire